Andrew Gaballa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew Gaballa has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Shada Jadam
Hypertrophic Cardiomyopathy Center, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA
11 shared publications - Milind Y. Desai
Heart, Vascular and Thoracic Institute, Cleveland Clinic , 9500 Euclid Avenue, Desk J1-5, Cleveland, OH 44195
10 shared publications - Bo Xu
Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA
8 shared publications Susan Ospina
8 shared publicationsMaran Thamilarasan
Hypertrophic Cardiomyopathy Center, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J1-5, Cleveland Clinic , Cleveland, OH 44195, USA
7 shared publicationsKaty Rutkowski
Hypertrophic Cardiomyopathy Center, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J1-5, Cleveland Clinic , Cleveland, OH 44195, USA
6 shared publications
Latest Publications
- 31 August 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 122 (15) , 2063-2065
Incremental prognostic value of late gadolinium enhancement in hypertrophic cardiomyopathy in a large contemporary cohort
Aims: Extensive late gadolinium enhancement (LGE) is recognized in contemporary hypertrophic cardiomyopathy (HCM) risk assessment, but the prognostic value of lower quantitative thresholds remains debated. We aimed to evaluate whether quantitative LGE provides independent and incremental prognostic information beyond established clinical and phenotypic risk markers. Methods and results: This large contemporary cohort included 3035 patients (median age 58 years, 57% men); 56% had LGE, including 242 (8%) with LGE > 10%. Most patients have obstructive hypertrophic cardiomyopathy (71%), 1498 (69%) of which subsequently underwent septal reduction therapy at a median of 43 days [interquartile range (IQR) 5–107) from the cardiac magnetic resonance (CMR) date (1485 myectomies and 13 alcohol septal ablations). Over a median of 8.8 years, 331 (11%) primary endpoints occurred [295 cardiovascular deaths (9.7%) and 36 appropriate implantable cardioverter–defibrillator discharges (1.3%)]. On multivariable Cox proportional hazards analysis [adjusted for standard clinical and CMR variables, higher %LGE (1.05 per 1% increase, 95% confidence interval 1.03–1.06; P < 0.001)] was associated with primary events. Compared with no LGE, LGE ≥10% was associated with higher risk of the composite endpoint. Conclusion: In this large contemporary HCM cohort, quantitative LGE was independently associated with long-term adverse outcomes. LGE ≥10% identified patients at significantly higher risk, and incorporation of LGE improved discrimination beyond ESC and AHA/ACC risk assessment.
- 31 August 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 122 (15) , 2063-2065
Incremental prognostic value of late gadolinium enhancement in hypertrophic cardiomyopathy in a large contemporary cohort
Aims: Extensive late gadolinium enhancement (LGE) is recognized in contemporary hypertrophic cardiomyopathy (HCM) risk assessment, but the prognostic value of lower quantitative thresholds remains debated. We aimed to evaluate whether quantitative LGE provides independent and incremental prognostic information beyond established clinical and phenotypic risk markers. Methods and results: This large contemporary cohort included 3035 patients (median age 58 years, 57% men); 56% had LGE, including 242 (8%) with LGE > 10%. Most patients have obstructive hypertrophic cardiomyopathy (71%), 1498 (69%) of which subsequently underwent septal reduction therapy at a median of 43 days [interquartile range (IQR) 5–107) from the cardiac magnetic resonance (CMR) date (1485 myectomies and 13 alcohol septal ablations). Over a median of 8.8 years, 331 (11%) primary endpoints occurred [295 cardiovascular deaths (9.7%) and 36 appropriate implantable cardioverter–defibrillator discharges (1.3%)]. On multivariable Cox proportional hazards analysis [adjusted for standard clinical and CMR variables, higher %LGE (1.05 per 1% increase, 95% confidence interval 1.03–1.06; P < 0.001)] was associated with primary events. Compared with no LGE, LGE ≥10% was associated with higher risk of the composite endpoint. Conclusion: In this large contemporary HCM cohort, quantitative LGE was independently associated with long-term adverse outcomes. LGE ≥10% identified patients at significantly higher risk, and incorporation of LGE improved discrimination beyond ESC and AHA/ACC risk assessment.
- Open Access
- 28 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (10)
Diffuse Fibrosis in Hypertrophic Cardiomyopathy
- 28 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (10)
Open AccessDiffuse Fibrosis in Hypertrophic Cardiomyopathy
- Open Access
- 15 July 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8) , 102859
Reappraisal of Surgical Threshold in Patients With Ascending Aortic Dilation
- 15 July 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8) , 102859
Open AccessReappraisal of Surgical Threshold in Patients With Ascending Aortic Dilation
- Open Access
- 13 July 2026
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 19 (9) , 1094-1106
Optimal Reclassification of Aortic Aneurysms
- 13 July 2026
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 19 (9) , 1094-1106
Open AccessOptimal Reclassification of Aortic Aneurysms
- Open Access
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e045827
Sex‐Based Differences in Long‐Term Outcomes of Patients With Ascending Aortic Dilation
Background: Thoracic ascending aortopathy (AA) is often asymptomatic and incidentally diagnosed, with surgical replacement recommended once it becomes aneurysmal. We report sex‐based characteristics and long‐term outcomes of patients with AA. Methods: This study analyzed 14 244 patients (21.1% women) with unrepaired AA (≥4 cm) diagnosed via echocardiography from 2010 to 2023, excluding those with acute aortic dissection/rupture at presentation (n=1179). Baseline data, including height‐indexed measurements (ascending aortic area height index and cross‐sectional area to height ratio), were collected. AA surgery and rates of aortic dissection/rupture during follow‐up were recorded. Cox proportional hazards and Kaplan–Meier survival analysis were performed for all‐cause mortality. Results: Women were older (63.6 versus 62.3 years) and had fewer comorbidities, including hypertension, diabetes, coronary artery disease, and dyslipidemia (all P 2 /m, both P P =0.04). At 0.86 years, 26.1% underwent surgery, with higher rates in women (28.2% versus 25.6%, P =0.002) and low in‐hospital mortality (0.9%). Over 6.2 years, women had worse survival (14.2% versus 11.2%, log‐rank P P P <0.001). Among unoperated patients (n=10 523), 62.9% of deaths and 72.4% of dissections/ruptures occurred in women with aortic diameters <5 cm. Conclusions: Despite fewer comorbidities and higher surgical rates, women with AA had worse long‐term survival. Sex‐specific thresholds for AA surgery may warrant consideration.
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e045827
Open AccessSex‐Based Differences in Long‐Term Outcomes of Patients With Ascending Aortic Dilation
Background: Thoracic ascending aortopathy (AA) is often asymptomatic and incidentally diagnosed, with surgical replacement recommended once it becomes aneurysmal. We report sex‐based characteristics and long‐term outcomes of patients with AA. Methods: This study analyzed 14 244 patients (21.1% women) with unrepaired AA (≥4 cm) diagnosed via echocardiography from 2010 to 2023, excluding those with acute aortic dissection/rupture at presentation (n=1179). Baseline data, including height‐indexed measurements (ascending aortic area height index and cross‐sectional area to height ratio), were collected. AA surgery and rates of aortic dissection/rupture during follow‐up were recorded. Cox proportional hazards and Kaplan–Meier survival analysis were performed for all‐cause mortality. Results: Women were older (63.6 versus 62.3 years) and had fewer comorbidities, including hypertension, diabetes, coronary artery disease, and dyslipidemia (all P 2 /m, both P P =0.04). At 0.86 years, 26.1% underwent surgery, with higher rates in women (28.2% versus 25.6%, P =0.002) and low in‐hospital mortality (0.9%). Over 6.2 years, women had worse survival (14.2% versus 11.2%, log‐rank P P P <0.001). Among unoperated patients (n=10 523), 62.9% of deaths and 72.4% of dissections/ruptures occurred in women with aortic diameters <5 cm. Conclusions: Despite fewer comorbidities and higher surgical rates, women with AA had worse long‐term survival. Sex‐specific thresholds for AA surgery may warrant consideration.
- 5 December 2025
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 19 (4) , 561-564
Treadmill Stress Echocardiography in Hypertrophic Cardiomyopathy
- 5 December 2025
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 19 (4) , 561-564
Treadmill Stress Echocardiography in Hypertrophic Cardiomyopathy
- Open Access
- 7 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (19)
Real‐World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification
Background: Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy treated at a multihospital referral center. Methods: We included 244 patients with obstructive hypertrophic cardiomyopathy (mean age, 64 years; 57% women, 21% with atrial fibrillation, 51% New York Heart Association class III, 82% on β‐blockers) treated with mavacamten for ≥3 months (171 for ≥12 months). Serial clinical and echocardiographic assessments were performed. Results: New York Heart Association class distribution improved over time: at 3 months 21% class I, 61% class II, and 18% class III; at 12 months 36% class I, 57% class II, and 8% class III. After a mean of 1.02 years, significant improvements were observed in resting and post‐Valsalva left ventricular outflow tract gradients (−31±33 and −57±46 mm Hg), interventricular septal thickness (−1.7±4 mm), left ventricular mass index (−9.5±32 g/m 2 ), left atrial volume index (−12±13 mL/m 2 ), E/e′ (−5.5±6.4), left ventricular global longitudinal strain (1.04%±3.1%), and various left atrial and right ventricular strain measures (all P <0.05). Temporary interruption occurred in 8 patients (3.2%), and 3 (1.2%) discontinued mavacamten permanently. There were 2 noncardiac deaths, 7 heart failure admissions, 14 cases of new‐onset atrial fibrillation, and 1 patient required septal reduction therapy. At the last visit, most patients were on 5 mg (49%) or 10 mg (26%) mavacamten. Conclusions: In this real‐world cohort, mavacamten treatment was associated with sustained symptomatic and echocardiographic improvements, suggesting a favorable disease‐modifying impact with minimal need for septal reduction therapy.
- 7 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (19)
Open AccessReal‐World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification
Background: Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy treated at a multihospital referral center. Methods: We included 244 patients with obstructive hypertrophic cardiomyopathy (mean age, 64 years; 57% women, 21% with atrial fibrillation, 51% New York Heart Association class III, 82% on β‐blockers) treated with mavacamten for ≥3 months (171 for ≥12 months). Serial clinical and echocardiographic assessments were performed. Results: New York Heart Association class distribution improved over time: at 3 months 21% class I, 61% class II, and 18% class III; at 12 months 36% class I, 57% class II, and 8% class III. After a mean of 1.02 years, significant improvements were observed in resting and post‐Valsalva left ventricular outflow tract gradients (−31±33 and −57±46 mm Hg), interventricular septal thickness (−1.7±4 mm), left ventricular mass index (−9.5±32 g/m 2 ), left atrial volume index (−12±13 mL/m 2 ), E/e′ (−5.5±6.4), left ventricular global longitudinal strain (1.04%±3.1%), and various left atrial and right ventricular strain measures (all P <0.05). Temporary interruption occurred in 8 patients (3.2%), and 3 (1.2%) discontinued mavacamten permanently. There were 2 noncardiac deaths, 7 heart failure admissions, 14 cases of new‐onset atrial fibrillation, and 1 patient required septal reduction therapy. At the last visit, most patients were on 5 mg (49%) or 10 mg (26%) mavacamten. Conclusions: In this real‐world cohort, mavacamten treatment was associated with sustained symptomatic and echocardiographic improvements, suggesting a favorable disease‐modifying impact with minimal need for septal reduction therapy.
- Open Access
- 17 March 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 11 (6) , 1324-1333
Real-World Artificial Intelligence–Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy
- 17 March 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 11 (6) , 1324-1333
Open AccessReal-World Artificial Intelligence–Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy
- 15 November 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 13 (4) , 631-640
Association of Histologic Findings With Long-Term Outcomes in Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients Undergoing Surgical Myectomy
- 15 November 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 13 (4) , 631-640
Association of Histologic Findings With Long-Term Outcomes in Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients Undergoing Surgical Myectomy